

BIBLIOGRAPHY

- Adair, T.H.** 2005. Growth regulation of the vascular system: an emerging role for adenosine. *American journal of physiology. Regulatory integrative and comparative physiology*, 289:283-296.
- Adler, C.H.** 2005. Nonmotor complications in Parkinson's disease. *Movement disorders*. 20:23-29.
- Adolfsson, R., Gottfries, C.G., Orelund, L., Wiberg, A., Winblad, B.** 1980. Increased activity of brain and platelet monoamine oxidase in dementia of Alzheimer type. *Life sciences*, 27:1029-1034.
- Agnati, L.F., Leo, G., Vergoni, A.V., Martínez, E., Hockemeyer, J., Lluís, C., Franco, R., Fuxe, K., Ferré, S.** 2004. Neuroprotective effect of L-DOPA co-administered with the adenosine A_{2A} receptor agonist CGS 21680 in an animal model of Parkinson's disease. *Brain research*, 64:155-64.
- Akkari, R., Burbiel, J.C., Hockemeyer, J., Müller, C.E.** 2006. Recent progress in the development of adenosine receptor ligands as anti-inflammatory drugs. *Current topics in medicinal chemistry*, 6:1375-99.
- Alexopoulos, G.S., Young, R.C., Lieberman, K.W., Shamoian, C.A.** 1987. Platelet MAO activity in geriatric patients with depression and dementia. *American journal of psychiatric rehabilitation*, 144:1480-1483.
- Anglade, P., Vyas, S., Javoy-Agid, F., Herrero, M.T., Michel, P.P., Marquez, J., Mouatt-Prigent, A., Ruberg, M., Hirsch, E.C., Agid, Y.** 1997. Apoptosis and autophagy in nigral neurons of patients with Parkinson's disease. *Histology and histopathology*, 12:25-31.
- Antoniou, K., Papadopoulou-Daifoti, Z., Hyphantis, T., Papathanasiou, G., Bekris, E., Marselos, M., Panlilio, L., Müller, C.E., Goldberg, S.R., Ferré, S.** 2005. A detailed behavioral analysis of the acute motor effects of caffeine in the rat: Involvement of adenosine A₁ and A_{2A} receptors. *Psychopharmacology*, 183:154-62.
- Ascherio, A., Zhang, S.M., Hernán, M.A., Kawachi, I., Colditz, G.A., Speizer, F.E., Willett, W.C.A.** 2001. Prospective study of caffeine consumption and the risk of Parkinson's disease in men and women. *American neurological association*, 50:56-63.
- Audet, M., Bouvier, M.** 2008. Insights into signaling from the β_2 -adrenergic receptor structure. *Nature chemical biology*, 4:397-403.
- Bara-Jimenez, W., Sherzai, A., Dimitrova, T., Favit, A., Bibbiani, F., Gillespie, M., Morris, M.J., Mouradian, M.M., Chase, T.N., Chase, M.D.** 2003. Adenosine A_{2A} receptor antagonist treatment of Parkinson's disease. *Neurology*, 3:293-296.

- Baraldi, P.G., Cacciari, B., Spalluto, G., Borioni, A., Viziano, M., Dionisotti, S., Ongini, E.** 1995. Current developments of A_{2A} adenosine receptor antagonists. *Current medicinal chemistry*, 2:707-722.
- Behan, W.M., Stone, T.W.** 2002. Enhanced neuronal damage by co-administration of quinolinic acid and free radicals, and protection by adenosine A_{2A} receptor antagonists. *British journal of pharmacology*, 135:1435-1442.
- Betarbet, R., Sherer, T.B., Di Monte, D.A., Greenmyre, J.T.** 2002. Mechanistic approaches to Parkinson's disease. *Brain pathology*, 12:499-510.
- Binda, C., Mattevi, A., Edmondson, D.** 2001. Structure-function relationships in flavoenzyme-dependent amine oxidations: a comparison of polyamine oxidase and monoamine oxidase. *Journal of biological chemistry*, 277:23973-23976.
- Blackburn, M.R., Vance, C.O., Morschl, E., Wilson, C.N.** 2009. Adenosine receptors and inflammation. *Handbook of experimental pharmacology*, 193: 215-269).
- Borroni, M.E., Huber, T.G., Kilpatrick, J.G.E., Norcross, D.R.** 2005. Adenosine receptor modulators, (Patent: WO 01062233).
- Bortolato, M., Chen, K., Shih, J.C.** 2008. Monoamine oxidase inactivation: From pathophysiology to therapeutics. *Advanced drug delivery reviews*, 60:1527-1533
- Bours, M.J., Swennen, E.L., Di Virgilio, F., Cronstein, B.N., Dagnelie, P.C.** 2006. Adenosine 5'-triphosphate and adenosine as endogenous signaling molecules in immunity and inflammation. *Pharmacology and therapeutics*, 112:358-404.
- Bové, J., Prou, D., Perier, C., Przedborski, S.** 2005. Toxin induced models of Parkinson's disease. *The journal of American society for experimental neurotherapeutics*, 2:484-494.
- Bruns, R.F., Lu, G.H., Pugsley, T.A.** 1986. Characterization of the A₂ adenosine receptor labeled by [³H]NECA in rat striatal membranes. *Molecular pharmacology*, 29:331-346.
- Chaudhuri, K.R., Healy, D.G., Schapira, A.H.** 2006. Non-motor symptoms of Parkinson's disease: diagnosis and management. *Lancet neurology*, 5:235-245.
- Chen, J.F., Huang, Z., Ma, J., Zhu, J., Moratalla, R., Standaert, D., Moskowitz, M.A., Fink, J.S., Schwarzschild, M.A.** 1999. A_{2A} adenosine receptor deficiency attenuates brain injury induced by transient focal ischemia in mice. *Journal of neuroscience*, 19:9192-200.

Chen, J., Xu, K., Petzer, J., Staal, R., Xu, Y., Beilstein, M., Sonsalla, P., Castagnoli, K., Castagnoli, N., Schwarzschild, M. 2001. Neuroprotection by caffeine and A_{2A} adenosine receptor inactivation in a model of Parkinson's disease. *Journal of neuroscience*, 21:1-6.

Cheng, Y., Prusoff, W.H. 1973. Relationship between the inhibition constant and the concentration of inhibitor which causes 50 percent inhibition of an enzymatic reaction. *Biochemical pharmacology*, 22:3099-3108.

Cheung, E.C., Melanson-Drapeau, L., Cregan, S.P., Vanderluit, J.L., Ferguson, K.L., McIntosh, W.C., Park, D.S., Bennett, S.A., Slack, R.S. 2005. Apoptosis-inducing factor is a key factor in neuronal cell death propagated by BAX-dependent and BAX-independent mechanisms. *Journal of neuroscience*, 25:1324-1334.

Chimenti, F., Bolasco, A., Manna, F., Secci, D., Chimenti, P., Granese, A., Befani, O., Turini, P., Cirilli, R., La Torre, F., Alcaro, S., Ortuso, F., Thierry, L. 2006. Synthesis, biological evaluation and 3D-QSAR of 1,3,5-trisubstituted-4,5-dihydro-(1*H*)-pyrazole derivatives as potent and highly selective monoamine oxidase A inhibitors. *Current medicinal chemistry*, 13:1411-1428.

Chimenti, F., Fioravanti, R., Bolasco, A., Manna, F., Chimenti, P., Secci, D., Befani, O., Turini, P., Ortuso, F., Alcaro, S. 2007. Monoamine oxidase isoform-dependent tautomeric influence in the recognition of 3,5-diaryl pyrazole inhibitors. *Journal of medicinal chemistry*, 50:425-428.

Chimenti, F., Fioravanti, R., Balasco, A., Chimenti, P., Secci, D., Rossi, F., Yanez, M., Orallo, F., Ortuso, F., Alcaro, S. 2009. Chalcones: A valid scaffold for monoamine oxidases inhibitors. *Journal of medicinal chemistry*. 52: 2818-2824.

Cieślak, M., Komoszyński, M., Wojtczak, A. 2008. Adenosine A_{2A} receptors in Parkinson's disease treatment. *Purinergic Signaling*, 4:305-312.

Cocconcelli, G., Diodato, E., Caricasole, A., Gaviraghi, G., Genesio, E., Ghiron, C., Magnoni, L., Pecchioli, E., Plazzib, P.V., Terstappena, G.C. 2008. Aryl azoles with neuroprotective activity-parallel synthesis and attempts at target identification. *Bioorganic and medicinal chemistry*, 16:2043-2052.

Coccorello, R., Breyse, N., Amalric, M., 2004. Simultaneous blockade of adenosine A_{2A} and metabotropic glutamate mGlu5 receptors increase their efficacy in reversing parkinsonian deficits in rats. *Neuropsychopharmacology*, 29:1451-1461.

Cohen, G., Spina, M.B. 1989. Deprenyl suppresses the oxidant stress associated with increased dopamine turnover. *Annals of neurology*, 26:689-690.

- Cohen, B.E., McAnaney, T.B., Park, E.S., Nung Jan, Y.N., Boxer, S.G., Yeh Jan, L.** 2002. Probing protein electrostatics with a synthetic fluorescent amino acid. *Proceedings of the national academy of sciences of the United States of America*, 102:965.
- Comella, C.L., Tanner, C.M.** 1995. Anticholinergic drugs. (In Koller, W.C., Paulson, G. eds. *Therapy of Parkinson's Disease*. 2nd ed. New York: Mercel Dekker Inc. p. 109-122).
- Correa, M., Wisniecki, A., Betz, A., Dobson, D.R., O'Neill, M.F., O'Neill, M.J., Salamone, J.D.** 2004. The adenosine A_{2A} antagonist KF17837 reverses the locomotor suppression and tremulous jaw movements induced by haloperidol in rats: Possible relevance to parkinsonism. *Behavioral brain research*, 148:47-54.
- Corrigan, F.M., Wienburg, C.L., Shore, R.F., Daniel, S.E., Mann, D.J.** 2000. Organochlorine insecticides in substantia nigra in Parkinson's disease. *Toxicology and environmental health*, 59:229-34.
- Costenla, A.R., de Mendonca, A., Ribeiro, J.A.** 1999. Adenosine modulates synaptic plasticity in hippocampal slices from aged rats. *Brain research*, 851:228-234.
- Cunha, R.A., Ferre, S., Vaugeois, J.M., Chen, J.F.** 2008. Potential therapeutic interest of adenosine A_{2A} receptors in psychiatric disorders. *Current pharmaceutical design*, 14:1512-1524.
- Dalvie, D.K., Kalgutkar, A.S., Khojasteh-Bakht, S.C., Obach, R.S., O'Donnell, J.P.** 2002. Biotransformation reactions of five-membered aromatic heterocyclic rings. *Chemical research in toxicology*, 15:269-299.
- David, H.N.** 2009. Towards a reconceptualization of striatal interactions between glutamatergic and dopaminergic neurotransmission and their contribution to the production of movements. *Current neuropharmacology*, 7:132-141
- Dauer, W., Przedborski, S.** 2003. Parkinson's disease: Mechanisms and models. *Neuron*, 39:889-909.
- Dluzen, D.E., McDermott, J.L.** 2000. Gender differences in neurotoxicity of the nigrostriatal dopaminergic system: Implications for Parkinson's disease. *Journal of gender- specific medicine*, 3:36-42.
- Domenici, M.R., Scattoni, M.L., Martire, A., Lastoria, G., Potenza, R.L., Borioni, A., Venerosi, A., Calamandrei, G., Popoli, P.** 2007. Behavioral and electrophysiological effects of the adenosine A_{2A} receptor antagonist SCH 58261 in R6/2 Huntington's disease mice. *Neurobiology of disease*, 28:197-205.
- Dorsey, E.R., Constantinescu, R., Thompson, J.P., Biglan, K.M., Holloway R.G., Kieburtz, K.** 2007. Projected number of people with Parkinson disease in the most populous nations. *Neurology*, 68:384-386.

- Dunwiddie, T.V., Masino, S.A.** 2001. The role and regulation of adenosine in the central nervous system. *Annual review of neuroscience*, 24:31-55.
- Edmondson, D.E., Mattevi, A., Binda, C., Li, M., Hubalek, F.** 2004. Structure and mechanism of monoamine oxidase. *Current medicinal chemistry*, 11:1983-1993.
- Edmondson, D.E., Binda, C., Mattevi, A.** 2007. Structural insights into the mechanism of amine oxidation by monoamine oxidases A and B. *Archives of biochemistry and biophysics*, 464:269-276.
- Elbaz, A., Levecque, C., Clavel, J., Vidal, J.S., Richard, F., Amouyel, P., Alperovitch, A., Chartier-Harlin, M.C., Tzourio, C.** 2004. CYP2D6 polymorphism, pesticide exposure, and Parkinson's disease. *Annals of neurology*, 55:430-4.
- Factor, S.A.** 1999. Dopamine agonists. *Medicine clinics in North America*, 83:415-443.
- Factor, S.** 2010. A long term study of istradefylline in subjects with fluctuating Parkinson's disease. *Parkinsonism and related disorders*, 16:423-426.
- Fahn, S., Cohen, G.** 1992 The oxidant stress hypothesis in Parkinson's disease: evidence supporting it. *Annals of neurology*, 32:804-812.
- Ferré, S., Fredholm, B.B., Morelli, M., Popoli, P., Fuxe, K.** 1997. Adenosine-dopamine receptor-receptor interactions as an integrative mechanism in the basal ganglia. *Trends in neurosciences*, 20:482-487.
- Fernandez, H.H., Greeley, D.R., Zweig, R.M., Wojcieszek, J., Mori, A., Sussman, N.M.** 2010. For the 6002-US-051 Study Group: Istradefylline as monotherapy for Parkinson's disease: Results of the 6002-US-051 trial. *Parkinsonism and related disorders*, 16:16-20.
- Fiebich, B.L., Biber, K., Lieb, K., van Calker, D., Berger, M., Bauer, J., Gebicke-Haerter, P.J.** 1996. Cyclooxygenase-2 expression in rat microglia is induced by adenosine A_{2A} receptors. *Glia*, 18:152-160.
- Finberg, J.P.M., Lamensdorf, I., Weinstock, M., Schwartz, M., Youdim, M.B.H.** 1999. Pharmacology of rasagiline (N-propargyl-1(R)-aminoindan). *Advances in neurology*, 80:495-501.
- Fink, J.S., Weaver, D.R., Rivkees, S.A., Peterfreund, R.A., Pollack, A.E., Adler, E.M., Reppert, S.M.** 1992. Molecular cloning of the rat A₂ adenosine receptor: selective co-expression with D₂ dopamine receptors in rat striatum. *Brain research*, 14:186-95.
- Fishman, P., Bar-Yehuda, S., Synowitz, M., Powell, J.D., Klotz, K.N., Gessi, S., Borea, P.A.** 2009. Adenosine receptors and cancer. *Handbook of experimental pharmacology*, 193:399-441.

- Fonfria, E., Dare, E., Benelli, M., Sunol, C., Ceccatelli, S.** 2002. Translocation of apoptosis inducing factor in cerebellar granule cells exposed to neurotoxic agents inducing oxidative stress. *European journal of neuroscience*, 16:2013-2016.
- Floran, B., Gonzalez, B., Floran, L., Erlij, D., Aceves, J.** 2005. Interactions between adenosine A_{2A} and dopamine D₂ receptors in the control of [³H] GABA release in the globus pallidus of the rat. *European journal of pharmacology*, 520:43-50.
- Fraaije, M. W.A., Mattevi, A.** 2000. Flavoenzymes: Diverse catalysts with recurrent features. *Trends in biochemical sciences*, 25:126-132.
- Fredduzzi, S., Moratalla, R., Monopoli, A., Cuellar, B., Xu, K., Ongini, E., Impagnatiello, F., Schwarzschild, M.A., Chen, J.F.** 2002. Persistent behavioral sensitization to chronic L-DOPA requires A_{2A} adenosine receptors. *Journal of neuroscience*, 22:1054-62.
- Fredholm, B.B.** 2007 Adenosine, an endogenous distress signal, modulates tissue damage and repair. *Cell death and differentiation*, 14:1315-1323.
- Fredholm, B.B., Chen, J.F., Masino, S.A., Vaugeois, J.M.** 2005. Actions of adenosine at its receptors in the CNS: Insights from knockouts and drugs. *Annual review of pharmacology and toxicology*, 45:385-412.
- Fredholm, B.B., IJzerman, A.P., Jacobson, K.A., Klotz, K.N., Linden, J.** 2001. International Union of Pharmacology. XXV. Nomenclature and classification of adenosine receptors. *Pharmacology reviews*, 53:527-552
- Fredholm, B.B.** 2010. Adenosine receptors as drug targets. *Experimental cell research*, 316:1284-1288.
- Fuxe, K., Ferré, S., Canals, M., Torvinen, M., Terasmaa, A., Marcellino, D., Goldberg, S.R., Staines, W., Jacobsen, K.X., Lluis, C., Woods, A.S., Agnati, L.F., Franco, R.** 2005. Adenosine A_{2A} and dopamine D₂ heteromeric receptor complexes and their function. *Journal of molecular neuroscience*, 26:209-220.
- Gao, Y., Phillis, J.W.** 1994. CGS 15943, an adenosine A₂ receptor antagonist, reduces cerebral ischemic injury in the Mongolian gerbil. *Life Sciences*, 55:61-65.
- Gerfen, C.R.** 2004. Basal Ganglia. (In Paxinos, G., ed. The rat nervous system. Amsterdam: Elsevier academic press. p. 445-508).
- Gerlach, M., Youdim, M.B., Riederer, P.** 1996. Pharmacology of selegiline. *Neurology*. 47:137-145.

- Gillespie, R.J., Bamford, S.J., Clay, A., Gaur, S., Haymes, T., Jackson, P.S., Jordan, A.M., Klenke, B., Leonardi, S., Liu, J., Mansell, H.L., Saadi, M., Simmonite, H., Stratton, G.C., Todd, R.S., Williamson, D.S., Yule, I.A.** 2009. Antagonists of the human A_{2A} receptor. Part 6. Further optimization of pyrimidine-4-carboxamides. *Bioorganic & medicinal chemistry*, 17:6590-6605.
- Go, M.L., Wu, X., Liu, X.L.** 2005. Chalcones: An update on cytotoxic and chemoprotective properties. *Current medicinal chemistry*, 12:481-499.
- Goggi, J., Theofilopoulos, S., Riaz, S.S.** 2000. The neuronal survival effects of rasagiline and deprenyl on fetal human and rat ventral mesencephalic neurones in culture. *Neuroreport*, 11:3937-3941.
- Hauber, W., Neuscheler, P., Nagel, J., Müller, C.E.** 2001. Catalepsy induced by a blockade of dopamine D_1 or D_2 receptors was reversed by a concomitant blockade of adenosine A_{2A} receptors in the caudate putamen of rats. *European journal of neuroscience*, 14:1287-1293.
- Hauser, R.A., Schwarzschild, M.A.** 2005. Adenosine A_{2A} receptor antagonists for Parkinson's disease: Rationale, therapeutic potential and clinical experience. *Drugs and aging*, 22:471-482.
- Headrick, J.P., Lasley, R.D.** 2009. Adenosine receptors and reperfusion injury of the heart. *Handbook of experimental pharmacology*, 193:189-214
- Hely, M.A., Fung, S.C., Morris, J.G.L.** 2000. Treatment of Parkinson's disease. *Journal of clinical neuroscience*, 7:484-494
- Hely, M.A., Morris, J.G.L., Reid, W.G.J., Traficante, R.** 1994. The Sydney multicentre study of Parkinson's disease: A randomised, prospective five year study comparing low dose bromocriptine with low dose levodopa-carbidopa. *Journal of neurology, neurosurgery & psychiatry*, 57:903-910.
- Hernan, M.A., Takkouche, B., Caamano-Isorna, F., Gestal-Otero, J.J.** 2002. A meta-analysis of coffee-drinking, cigarette smoking and the risk of Parkinson's disease. *Annals of neurology*, 52:276-284.
- Hodgson, R.A., Bedard, P.J., Varty, G.B., Kazdoba, T.M., Di Paolo, T., Grzelak, M.E., Pond, A.J., HadjTahar, A., Belanger, N., Gregoire, L., Dare, A., Neustadt, B.R., Stamford, A.W., Hunter, J.C.** 2010. Preladenant, a selective A_{2A} receptor antagonist, is active in primate models of movement disorders. *Experimental neurology*, 225:384-390.
- Hubalek, F., Binda, C., Khalil, A., Li, M., Mattevi, A., Castagnoli, N., Edmondson, D.E.** 2005. Demonstration of isoleucine 199 as a structural determinant for the selective inhibition of human monoamine oxidase B by specific reversible inhibitors. *Journal of biological chemistry*, 280:15761-15766.

- Fernandez, H.H., Chen, J.J.** 2007. Monoamine oxidase-B inhibition in the treatment of Parkinson's disease. *Pharmacotherapy*, 27:174-185.
- Ikeda, K., Kurokawa, M., Aoyama, S., Kuwana, Y.** 2002. Neuroprotection by adenosine A_{2A} receptor blockade in experimental models of Parkinson's disease. *Journal of neurochemistry*, 80:262-70.
- Ishiwari, K., Madson, L.J., Farrar, A.M., Mingote, S.M., Valenta, J.P., DiGianvittorio, M.D., Frank, L.E., Correa, M., Hockemeyer, J., Müller, C., Salamone, J.D.** 2007. Injections of the selective adenosine A_{2A} antagonist MSX-3 into the nucleus accumbens core attenuate the locomotor suppression induced by haloperidol in rats. *Behavioral brain research*, 178:190-199.
- Jaakola, V.P., Griffith M.T., Hanson, M.A., Cherezov, V., Chien, Y.T., Lane, J.R., IJzerman, A.P., Stevens, R.C.** 2008. The 2.6 angstrom crystal structure of a human A_{2A} adenosine receptor bound to an antagonist. *Science*, 322:1211-1217.
- Jacobson, K.A., Gao, Z.G.** 2006. Adenosine receptors as therapeutic targets. *Nature reviews. Drug discovery*, 5:247-264.
- Jenner, P.** 2005. Istradefylline, a novel adenosine A_{2A} receptor antagonist, for the treatment of Parkinson's disease. *Expert opinion on investigational drugs*, 14:729-38.
- Jenner, P., Mori, A., Hauser, R., Morelli, M., Fredholm B., Chen, J.F.** 2009. Adenosine, adenosine A_{2A} antagonists and Parkinson's disease. *Parkinsonism related disorders*, 15:406-413.
- Jones, P.A., Smith, R.A., Stone, T.W.** 1998. Protection against hippocampal kainate excitotoxicity by intracerebral administration of an adenosine A_{2A} receptor antagonist. *Brain research*, 800:328-335.
- Kachroo, A., Orlando, L.R., Grandy, D.K., Chen, J.F., Young, A.B., Schwarzschild, M.A.** 2005. Interactions between metabotropic glutamate 5 and adenosine A_{2A} receptors in normal and parkinsonian mice. *Journal of neuroscience*, 25:10414-10419.
- Kafka, S.H., Corbett, R.** 1996. Selective adenosine A_{2A} receptor/dopamine D₂ receptor interactions in animal models of schizophrenia. *European journal of pharmacology*, 295:147-54.
- Kanda, T., Jackson, M.J., Smith, L.A., Pearce, R.K.B., Nakamura, J., Kase, H.** 1998a. Adenosine A_{2A} antagonist: a novel antiparkinsonian agent that does not provoke dyskinesia in Parkinsonian monkeys. *Annals of neurology*, 43:507-513.
- Kanda, T., Tashiro, T., Kuwana, Y., Jenner, P.** 1998b. Adenosine A_{2A} receptors modify motor function in MPTP-treated common marmosets. *Neuroreport*, 9:2857-2860.

- Katritch, V., Kufareva, I., Abagyan, R.** 2010. Structure based prediction of subtype-selectivity for adenosine receptor antagonists. *Neuropharmacology*, 60:108-15.
- Kim, J., Jiang, Q., Glashofer, M., Yehle, S., Wess, J. Jacobson, K. A.** 1996. Glutamate residues in the second extracellular loop of the human A_{2A} adenosine receptor are required for ligand recognition. *Molecular pharmacology*, 49:683-691.
- Kim, J., Wess, J., van Rhee, A.M., Schoneberg, T., Jacobson, K.A.** 1995. Site-directed mutagenesis identifies residues involved in ligand recognition in the human A_{2A} adenosine receptor. *Journal of biological chemistry*, 270:13987-13997.
- Kish, S.J., Shannak, K., Rajput, A., Deck, J.H.N., Hornykiewicz, O.** 1992. Aging produces a specific pattern of striatal dopamine loss: Implications for the etiology of idiopathic Parkinson's disease. *Journal of neurochemistry*, 58:642-648.
- Knoll, J.** 2000. (-)-Deprenyl (selegiline): Past, present and future. *Neurobiology*, 8:179-199.
- Kobilka, B.K., Deupi, X.** 2007. Conformational complexity of G-protein-coupled receptors. *Trends in pharmacology science*, 28:397-406.
- Langston, J.W., Koller, W.C., Giron, L.T.** 1992. Etiology of Parkinson's disease. (In Olanow, C.W., Lieberman, A.N., eds. The scientific basis for the treatment of Parkinson's disease. Park Ridge, NJ: Parthenon. p.33-58.
- Lappas, C.M., Rieger, J.M., Linden, J.** 2005. A_{2A} adenosine receptor induction inhibits IFN gamma production in murine CD4 β T cells. *The journal of immunology*, 174:1073-80.
- Lebon, G., Warne, T., Edwards, P.C., Bennett, K., Langmead, C.J., Leslie A.G.W., Tate, C.G.** 2011. Agonist-bound adenosine A_{2A} receptor structures reveal common features of GPCR activation. *Nature*, 474:521-525.
- Ledent, C., Vaugeois, J.M., Schiffmann, S.N., Pedrazzini, T., El Yacoubi, M., Vanderhaeghen, J.J., Costentin, J., Heath, J.K., Vassart, G., Parmentier, M.** 1997. Aggressiveness, hypoalgesia and high blood pressure in mice lacking the adenosine A_{2A} receptor. *Nature*, 388:674-678.
- Lee, K.W., Hong, J.H., Choi, I.Y., Che, Y., Lee, J.K., Yang, S.D., Song, C.W., Kang, H.S., Lee, J.H. Noh, J.S., Shin, H.S., Han, P.L.** 2002. Impaired D_2 dopamine receptor function in mice lacking type 5 adenylyl cyclase. *Journal of neuroscience*, 22:7931-7940.
- Lee, H.K., Choi, S.S., Han, K.J., Han, E.J., Suh, H.W.** 2004. Roles of adenosine receptors in the regulation of kainic acid-induced neurotoxic responses in mice. *Molecular brain research*, 125:76-85.

- Lee, Y.C., Chien, C.L., Sun, C.N., Huang, C.L., Huang, N.K., Chiang, M.C., Lai, H.L., Lin, Y.S., Chou, S.Y., Wang, C.K., Tai, M.H., Liao, W.L., Lin, T.N., Liu, F.C., Chern, Y.** 2003. Characterization of the rat A_{2A} adenosine receptor gene: a 4,8-kb promoter-proximal DNA fragment confers selective expression in the central nervous system. *European journal of neuroscience*, 18:1786-1796.
- LeWitt, P.A., Taylor, D.C.** 2008. Protection against Parkinson's disease progression: Clinical experience. *Journal of the American society for experimental neurotherapeutics*, 5:210-225.
- Lipton, S.A., Rosenberg, P.A.** 1994. Excitatory amino acids as a final common pathway for neurologic disorders. *Journal of medicine*, 330:613-622.
- Magnani, F., Shibata, Y., Serrano-Vega, M.J., Tate, C.G.** 2008. Co-evolving stability and conformational homogeneity of the human adenosine A_{2A} receptor. *Proceedings of the national academy of sciences of the United States of America*, 105:10744-10749.
- Maignan, J., Lang, G., Malle, G., Restle, S., Shroot, B.** 1989. Bicyclic naphthalenic derivatives, a process for preparing the same and human or veterinary medicines and cosmetic compositions containing said derivatives, (Patent: US 4826969).
- Mally, J., Stone, T.W.** 1994. The effect of theophylline on parkinsonian symptoms. *Journal of pharmacy and pharmacology*, 46:515-517.
- Malec, D.** 1997. Haloperidol-induced catalepsy is influenced by adenosine receptor antagonists. *Polish journal of pharmacology*, 49:323-327.
- Mantri, M., de Graaf, O., van Veldhoven, J., Göblyös, A., von Frijtag Drabbe Kunzel, J. K., Mulder-Krieger, T., Link, R., de Vries, H., Beukers, M. W., Brussee, J., IJzerman, A. P.** 2008. 2-Amino-6-furan-2-yl-4-substitutednicotinonitriles as A_{2A} adenosine receptor antagonists. *Journal of medicinal chemistry*, 51:4449-4455.
- Mason, R.P., Olmstead, E.G., Jacob, R.F.** 2000. Antioxidant activity of the monoamine oxidase B inhibitor lazabemide. *Biochemical pharmacology*, 60:709-716.
- Matasi, J.J., Caldwell, P., Hao, J., Neustadt, B., Arik, L., Foster, C.J., Lachowicz, J., Tulshian, D.B.** 2005. The discovery and synthesis of novel adenosine receptor A_{2A} antagonists. *Bioorganic & medicinal chemistry*, 15:1333-1336.
- Miller, J.R., Edmondson, D.E.** 1999. Structure-activity relationships in the oxidation of para-substituted benzylamine analogues by recombinant human liver monoamine oxidase A. *Biochemistry*. 38:13670-83.
- Mitoma, J., Ito, A.** 1992. Mitochondrial targeting signal of rat liver monoamine oxidase B is located at its carboxy terminus. *Journal of biochemistry*, 111:20-24.

- Mochizuki, H., Goto, K., Mori, H., Mizuno, Y.** 1996. Histochemical detection of apoptosis in Parkinson's disease. *Journal of neurological sciences*, 137:120-123.
- Monopoli, A., Lozza, G., Forlani, A., Mattavelli, A., Ongini, E.** 1998. Blockade of adenosine A_{2A} receptors by SCH 58261 results in neuroprotective effects in cerebral ischaemia in rats. *Neuroreport*, 9:3955-3959.
- Moo-Puc, R.E., Gongora-Alfaro, J.L., Alvarez-Cervera, F.J., Pineda, J.C., Arankowsky-Sandoval, G., Heredia-Lopez, F.** 2003. Caffeine and muscarinic antagonists act in synergy to inhibit haloperidol-induced catalepsy. *Neuropharmacology*, 45:493-503.
- Moreau, J.L., Huber, G.** 1999. Central adenosine A_{2A} receptors: An overview. *Brain research reviews*. 31:65-82.
- Morelli, M., Carta, A.R., Jenner, P.** 2009. Adenosine A_{2A} receptors and Parkinson's Disease. *Handbook of experimental pharmacology*, 193:589-615.
- Morelli, M., Di Paolo, T., Wardas, J., Calon, F., Xiao, D., Schwarzschild, M.A.** 2007. Role of adenosine A_{2A} receptors in parkinsonian motor impairment and L-DOPA-induced motor complications. *Progress in neurobiology*, 83:293-309.
- Morelli, M., Wardas, J.** 2001. Adenosine A_{2A} receptor antagonist: potential therapeutic and neuroprotective effects in Parkinson's disease. *Neurotoxicity research*, 3:545-556.
- Mori, A., Shindou, T.** 2003. Modulation of GABAergic transmission in the striatopallidal system by adenosine A_{2A} receptors: A potential mechanism for the antiparkinsonian effects of A_{2A} antagonists. *Neurology*, 61:44-48.
- Müller, C.E., Ferré S.** 2007. Blocking striatal adenosine A_{2A} receptors: New strategy for basal ganglia disorders. *Recent patents on CNS drug discovery*, 2:1-21.
- Müller, C.E., Shi, D., Manning, M., Daly, J.W.** 1993. Synthesis of paraxanthine analogs (1,7-disubstituted xanthines) and other xanthines unsubstituted at the 3-position: Structure-activity relationships at adenosine receptors. *Journal of medicinal chemistry*, 36:3341-3349.
- Murray, R., Granner, D., Mayes, P., Rodwell, V.** 2003. Enzyme kinetics. (In Murray, R., Granner, D., Mayes, P., Rodwell, V. eds. Harper's Illustrated Biochemistry. 26th ed), McGraw-Hill. p.62-73.
- Mustafa, S.J., Morrison, R.R., Teng, B., Pelleg, A.** 2009. Adenosine receptors and the heart: role in regulation of coronary blood flow and cardiac electrophysiology. *Handbook of experimental pharmacology*, 193:161-188.

- Nagatsu, T.** 2004. Progress in monoamine oxidase (MAO) research in relation to genetic engineering. *Neurotoxicology*, 25:11-20.
- Normile, H.J., Barraco, R.A.** 1991. N6-Cyclopentyladenosine impairs passive avoidance retention by selective action at A₁ receptors. *Brain research bulletin*, 27:101-104.
- Novaroli, L., Reist, M., Favre, E., Carotti, A., Catto, M., Carrupt, P.A.** 2005. Human recombinant monoamine oxidase B as a reliable and efficient enzyme source for inhibitor screening. *Bioorganic & Medicinal Chemistry*, 13:6212 - 6217.
- Nurmi, E., Ruottinen, H.M., Kaasinen, V., Bergman, J., Haaparanta, M., Solin, O., Rinne, J.O.** 2000. Progression in Parkinson's disease: a positron emission tomography study with a dopamine transporter ligand 18F CFT. *Annals of neurology*, 47:804-8.
- Ohta, A., Sitkovsky, M.** 2001. Role of G-protein-coupled adenosine receptors in downregulation of inflammation and protection from tissue damage. *Nature*, 414:916-20.
- Olanow, C.W.** 1992. An introduction to the free radical hypothesis in Parkinson's disease. *Annals of neurology*, 32:S2-S9.
- Ongini, E., Dionisotti, S., Gessi, S., Irenius, E., Fredholm, B.B.** 1999. Comparison of CGS15943, ZM 241385 and SCH 58261 as antagonists at human adenosine receptors. *Naunyn-Schmiedeberg's archives of pharmacology*, 359:7-10.
- Ossowska, K., Konieczny, J., Wolfarth, S., Pilc, A.** 2005. MTEP, a new selective antagonist of the metabotropic glutamate receptor subtype 5 (mGluR5), produces antiparkinsonian-like effects in rats. *Neuropharmacology*, 49:447-455.
- Pahwa, R., Factor, S.A., Lyons, K.E., Ondo, W.G., Gronseth, G., Bronte-Stewart, H., Hallett, M., Miyasaki, J., Stevens, J., Weiner, W.J.** 2006. Practice parameter: Treatment of Parkinson's disease with motor fluctuations and dyskinesia. *Neurology*, 66:983-995.
- Parent A., Hazrati, I.L.N.** 1995. Functional anatomy of the basal ganglia. The cortico-basal ganglia-thalamo-cortical loop. *Brain research reviews*, 20:91-127.
- Parkinson's disease study group.** 1993. A controlled trial of lazabemide in untreated Parkinson's disease. *Annals of neurology*, 33:350-356.
- Pavia, D.L., Lampman, G.M., Kriz, G.S., Vyvyan, J.R.** 2009. Introduction to spectroscopy. 4th edition. Belmont: Brooks & Cole. p.277.

- Popoli, P., Pezzola, A., Torvinen, M., Reggio, R., Pintor, A., Scarchilli, L., Fuxe, K., Ferre, S.** 2001. The selective mGlu5 receptor agonist CHPG inhibits quinpirole-induced turning in 6-hydroxydopamine-lesioned rats and modulates the binding characteristics of dopamine D₂ receptors in the rat striatum: Interactions with adenosine A_{2A} receptors. *Neuropsychopharmacology*, 25:505-513.
- Popoli, P., Frank, C., Tebano, M.T., Potenza, R.L., Pintor, A., Domenici, M.R., Nazzicone, V., Pezzola, A., Reggio, R.** 2003. Modulation of glutamate release and excitotoxicity by adenosine A_{2A} receptors. *Neurology*, 61:69-71.
- Porras, G., Fernagut, P.O., Bezard, E.** 2010. Parkinson's disease: Animal models. (In Kompoliti, K., Metman, L.V., eds. *Encyclopaedia of movement disorders*. Amsterdam: Elsevier Academic Press. p. 420-422).
- Poucher, S.M., Keddie, J.R., Singh, P., Stoggall, S.M., Caulkett, P.W.R., Jones, G., Collis, M.G.** 1995. The *in vitro* pharmacology of ZM241385, a potent, non-xanthine, A_{2A} selective adenosine receptor antagonist. *British journal of pharmacology*, 115:1096-1102.
- Raepffel, S., Gaudette, F., Delorme, D.** 2007. Inhibitors of histone deacetylase, (Patent: US 7282608 B2).
- Rascol, O., Brooks, D.J., Melamed, E., Oertel, W., Poewe, W., Stocchi, F., Tolosa, E.** 2005. Rasagiline as an adjunct to levodopa in patients with Parkinson's disease and motor fluctuations (LARGO, lasting effect in adjunct therapy with rasagiline given once daily, study): a randomized, double blind, parallel-group trial. *Lancet*, 365:947-950.
- Reix, S., Mechawar, N., Susin, S.A., Quirion, R., Krantic, S.** 2007. Expression of cortical and hippocampal apoptosis-inducing factor (AIF) in aging and Alzheimer's disease. *Neurobiology aging*, 28:351-356.
- Richardson, C.M., Gillespie, R.J., Williamson, D.S., Jordan, A.M., Fink, A., Knight, A.R., Sellwood, D.M., Misra, A.** 2006. Identification of non-furan containing A_{2A} antagonists using database mining and molecular similarity approaches. *Bioorganic & medicinal chemistry*, 16:5993-5997.
- Riederer, P., Lachenmayer, L., Laux, G.** 2004. Clinical applications of MAO-inhibitors. *Current medicinal chemistry*, 11:2033-2043.
- Rodrigues, R.J., Alfaro, T.M., Rebola, N., Oliveira, C.R., Cunha, R.A.** 2005. Co-localization and functional interaction between adenosine A_{2A} and metabotropic group 5 receptors in glutamatergic nerve terminals of the rat striatum. *Journal of neurochemistry*, 92:433-441.

Rodwell, V. W. 1993. Enzymes: Kinetics. (In Murray, R.K., Granner, D.K., Mayes, P.A., Rodwell, V.W. ed. Harper's biochemistry. 23rd edition. New Jersey: Appleton & Lange. p.60-70).

Romanowska, M., Komoszyński, M. 2002. Adenosine – neurotransmitter and neuromodulator in central nervous system. *Progress in biochemical pharmacology*, 48:230-238.0

Rose, S., Jackson, M.J., Smith, L.A., Stockwell, K., Johnson, L., Carminati, P., Jenner, P. 2006. The novel adenosine A_{2A} receptor antagonist ST1535 potentiates the effects of threshold dose of L-DOPA in MPTP treated common marmosets. *European journal of pharmacology*, 546:82-87.

Rosin, D., Hettinger, B., Lee, A., Linden, J. 2003. Anatomy of adenosine A_{2A} receptors in brain. *Neurology*, 61:12-18.

Rueping, M., Bootwicha, T., Baars, H., Sugiono, E. 2011. Continuous-flow hydration-condensation reaction: synthesis of α,β -unsaturated ketones from alkynes and aldehydes by using a heterogeneous solid acid catalyst. *Beilstein journal of organic chemistry*, 7:1680-1687.

Salamone, J.D., Ishiwari, K., Betz, A.J., Farrar, A.M., Mingote, S.M., Font, L., Hockemeyer, J., Müller, C.E., Correa, M. 2008. Dopamine/adenosine interactions related to locomotion and tremor in animal models: Possible relevance to parkinsonism. *Parkinsonism and related disorders*, 14:130-134.

Schapira, A.H., Mann, V.M., Cooper, J.M., Krige, D., Jenner, P.J., Marsden, C.D. 1992. Mitochondrial function in Parkinson's disease. *Annals of neurology*, 32:116-124.

Schiffmann, S.N., Fisone, G., Moresco, R., Cunha, R.A., Ferre, S. 2007. Adenosine A_{2A} receptors and basal ganglia physiology. *Progress in neurobiology*, 83:277-292.

Schiffmann, SN., Jacobs, O., Vanderhaeghen, J.J. 1991. Striatal restricted adenosine A_{2A} receptor is expressed by enkephalin but not by substance P neurons: An in situ hybridization histochemistry study. *Journal of neurochemistry*, 57:1062-1067

Schwarzschild, M.A., Agnati, L., Fuxe, K., Chen, J.F., Morelli, M. 2006. Targeting adenosine A_{2A} receptors in Parkinson's disease. *Trends in neurosciences*, 29:647-654.

Sebastiao, A.M., Ribeiro, J.A. 2009. Adenosine receptors and the central nervous system. *Handbook of experimental pharmacology*, 193:471-534.

Serrano-Vega, M.J., Magnani, F., Shibata, Y., Tate, C.G. 2008. Conformational thermostabilization of the β_1 -adrenergic receptor in a detergent-resistant form. *Proceedings of the national academy of sciences of the United States of America*, 105:877-882.

Sharma, M., Chaturvedi, V., Manju, Y.K., Bhatnagar, S., Srivastava, K., Puri, S.K., Chauhan, P.M.S. 2009. Substituted quinolinyl chalcones and quinolinyl pyrimidines as a new class of anti-infective agents. *European journal of medicinal chemistry*, 44:2081-2091.

Shih, J.C., Chen, K., Ridd, M.J. 1999. Monoamine oxidase: From genes to behaviour. *Annual review of neuroscience*, 22:197-217.

Shiozaki, S., Ichikawa, S., Nakamura, J., Kitamura, K., Yamada, K., Kuwana, Y. 1999. Actions of adenosine A_{2A} receptor antagonist KW-6002 on drug-induced catalepsy and hypokinesia caused by reserpine or MPTP. *Psychopharmacology*, 147:90-95.

Shook, B.C., Rassnick, S., Hall, D., Rupert, K.C., Heintzelman, G.R., Hansen, K., Chakravarty, D., Bullington, J.L., Scannevin, R.H., Magliaro, B., Westover, L., Carroll, K., Lampron, L., Russell, R., Branum, S., Wells, K., Damon, S., Youells, S., Li, X., Osbourne, M., Demarest, K., Tang, Y., Rhodes, K., Jackson, P.F. 2010a. Methylene amine substituted arylindenopyrimidines as potent adenosine A_{2A}/A_1 antagonists. *Bioorganic & medicinal chemistry letters*, 20:2864-2867.

Shook, B.C., Rassnick, S., Chakravarty, D., Wallace, N., Ault, M., Crooke, J., Barbay, J.K., Wang, A., Leonard, K., Powell, M.T., Alford, V., Hall, D., Rupert, K.C., Heintzelman, G.R., Hansen, K., Bullington, J.L., Scannevin, R.H., Carroll, K., Lampron, L., Westover, L., Russell, R., Branum, S., Wells, K., Damon, S., Youells, S., Beauchamp, D., Li, X., Rhodes, K., Jackson, P.F. 2010b. Optimization of arylindenopyrimidines as potent adenosine A_{2A}/A_1 antagonists. *Bioorganic & medicinal chemistry letter*, 20:2868-71.

Shook, B.C., Rassnick, S., Osborne, M.C., Davis, S., Westover, L., Boulet, J., Hall, D., Rupert, K.C., Heintzelman, G.R., Hansen, K., Chakravarty, D., Bullington, J.L., Russell, R., Branum, S., Wells, K.M., Damon, S., Youells, S., Li, X., Beauchamp, D.A., Palmer, D., Reyes, M., Demarest, K., Tang, Y., Rhodes, K., Jackson, P.F. 2010c. In vivo characterization of a dual adenosine A_{2A}/A_1 receptor antagonist in animal models of Parkinson's disease. *Journal of medicinal chemistry*, 53:8104-15.

Shook, B.C., Rassnick, S., Wallace, N., Crooke, J., Ault, M., Chakravarty, D., Barbay, J.K., Wang, A., Powell, M.T., Leonard, K., Alford, V., Scannevin, R.H., Carroll, K., Lampron, L., Westover, L., Lim, H., Russell, R., Branum, S., Wells, K.M., Damon, S., Youells, S., Li, X., Beauchamp, D.A., Rhodes, K., Jackson, P.F. 2012. Design and characterization of optimized adenosine A_{2A}/A_1 receptor antagonists for the treatment of Parkinson's disease. *Journal of medicinal chemistry*, 55:1402-1417.

Silverman, R. 1995. Radical ideas about monoamine oxidase B. *Accounts of chemical research*. 28:335-342.

Singh, N., Pillay, V., Choonara, Y.E. 2007. Advances in the treatment of Parkinson's disease. *Progress in neurobiology*, 81:29-44.

Slee, D.H., Chen, Y., Zhang, X., Moorjani, M., Lanier, M.C., Lin, E., Reuter, J.K., Williams, J.P., Lechner, S.M., Markison, S., Malany, S., Santos, M., Gross, R.S., Jalali, K., Sai, Y., Zuo, Z., Yang, C., Castro-Palomino, J.C., Crespo, M.I., Prat, M., Gaul, S., Diaz, J.L., Saunders, J. 2008a. 2-Amino-N-pyrimidine-4-yl acetamides as A_{2A} receptor antagonists: 1. Structure-activity relationship and optimization of heterocyclic substituents. *Journal of medicinal chemistry*, 51:1719-1729.

Slee, D.H., Zhang, X., Moorjani, M., Lin, E., Lanier, M.C., Chen, Y., Reuter, J.K., Lechner, S.M., Markison, S., Malany, S., Joswig, T., Santos, M., Gross, R.S., Williams, J.P., Castro-Palomino, J.C., Crespo, M.I., Prat, M., Gaul, S., Diaz, J.L., Wen, J., O'Brian, Z., Saunders, J. 2008b. Identification of novel, water-soluble, 2-amino-N-pyrimidin-4-yl acetamides as A_{2A} receptor antagonists with *in vivo* efficacy. *Journal of medicinal chemistry*, 51:400-406.

Soderstrom, K.E., Baum, G., Kordower, J.H. 2009. Animal models for Parkinson's disease, (*In* Squire, L.R., ed. *Encyclopedia of neuroscience*, Elsevier Academic Press, Oxford, UK: 455-463).

Son, S., Ma, J., Kondou, Y., Yoshimura, M., Yamashita, E. Tsukahara, T. 2008. Structure of human monoamine oxidase A at 2.2-Å resolution: The control of opening the entry for substrates/inhibitors. *Proceedings of the national academy of sciences of the United States of America*, 105:5739-5744.

Standaert, D.G., Young, A.B. 2006. Treatment of central nervous system degenerative disorders. (*In* Brunton, L.L., Lazo, J.S., Parker, K.L. ed. *Goodman & Gilman's: The pharmacological basis of therapeutics* 11th edition. New York: McGraw-Hill. p.527-545).

Stone, T.W., Behan, W.M. 2007. Interleukin-1beta but not tumor necrosis factor-alpha potentiates neuronal damage by quinolinic acid: protection by an adenosine A_{2A} receptor antagonist. *Journal of neuroscience research*, 85:1077-1085.

Svenningsson, P., Nomikos, G.G., Ongini, E., Fredholm, B.B. 1997. Antagonism of adenosine A_{2A} receptors underlies the behavioural activating effect of caffeine and is associated with reduced expression of messenger RNA for NGFI-A and NGFI-B in caudate-putamen and nucleus accumbens. *Neuroscience*, 79:753-764.

Svenningsson, P., Le Moine, C., Fisone, G., Fredholm, B.B. 1999. Distribution, biochemistry and function of striatal adenosine A_{2A} receptors. *Progress in neurobiology*, 59:355-396.

Talpade, D.J., Greene, J.G., Higgins, D.S., Jr. & Greenamyre, J.T. 2000. *In vivo* labeling of mitochondrial complex I (NADH:ubiquinone oxidoreductase) in rat brain using [³H]dihydrorotenone. *Journal of neurochemistry*, 75:2611-2621.

- Tanner, C.M., Ottman, R. Goldman, S.M. Ellenberg, J., Chan, P., Mayeux, R., Langston, J.W.** 1999. Parkinson's disease in twins: an etiologic study. *The journal of the American medical association*, 281:341-346.
- Thanh, N.D., Mai, N.T.T.** 2009. Synthesis of *N*-tetra-*O*-acetyl- β -D-glucopyranosyl-*N'*-(4',6' -diarylpurimidin-2'-yl) thioureas. *Carbohydrate research*, 344:2399-2405.
- Tipton, K.F.** 1997. Monoamine oxidase inhibitors and pressor response to dietary amines. *Biomedical chemistry*, 43:494-503.
- Trevitt, J., Vallance, C., Harris, A., Goode, T.** 2009. Adenosine antagonists reverse the cataleptic effects of haloperidol: Implications for the treatment of Parkinson's disease. *Pharmacology, biochemistry and behavior*, 92:521-527.
- Tsukerman, S. V., Nikitchenko, V. M., Lavrushin, V. F.** 1968. Spectra and halochromism of some furan and thiophene analogs of chalcones. *Chemical journal of Ukraine*, 34:1048-54.
- Ueda, K., Fukushima, H., Masliah, E., Xia, Y., Iwai, A., Yoshimoto, M., Otero, D.A., Kondo, J., Ihara, Y., Saitoh, T.** 1993. Molecular cloning of cDNA encoding an unrecognized component of amyloid in Alzheimer disease. *Proceedings of the national academy of sciences of the United States of America*, 90:11282-11286.
- Von Campenhausen, S., Bornschein, B., Wick, R., Botzel, K., Sampaio, C., Poewe, W., Oertel, W., Siebert, U., Berger, K., Dodel, R.** 2005. Prevalence and incidence of Parkinson's disease in Europe. *Neuropsychopharmacology*, 15:473-490.
- Walker, M.C., Edmondson, D.E.** 1994. Structure-activity relationships in the oxidation of benzylamine analogues by bovine liver mitochondrial monoamine oxidase B. *Biochemistry*, 33:7088-98.
- Ward, R.P., Dorsa, D.M.** 1999. Molecular and behavioural effects mediated by Gs-coupled adenosine A_{2A}, but not serotonin 5-HT₆ receptors following antipsychotic administration. *Neuroscience*, 89:927-938.
- Wardas, J., Konieczny, J., Lorenc-Koci, E.** 2001. SCH 58261, an A_{2A} adenosine receptor antagonist, counteracts the parkinsonian-like muscle rigidity in rats. *Synapse*, 41:160-171.
- Wilson, C.N., Nadeem, A., Spina, D., Brown, R., Page, C.P., Mustafa, S.J.** 2009. Adenosine receptors and asthma. *Handbook of experimental pharmacology*, 193:329-362.
- Xu, K., Xu, Y.H., Chen, J.F., Schwarzschild, M.A.** 2002. Caffeine's neuroprotection against 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine toxicity shows no tolerance to chronic caffeine administration in mice. *Neuroscience letters*, 322:13-16.


- Youdim, M.B., Edmondson, D., Tipton, K.F.** 2006. The therapeutic potential of monoamine oxidase inhibitors. *Nature reviews neuroscience*, 7:295-309.
- Youdim, M.B.H, Weinstock, M.** 2004. Therapeutic applications of selective and non-selective inhibitors of monoamine oxidase A and B that do not cause significant tyramine potentiation. *Neurotoxicology*, 15:243-250.
- Zalewska-Kasubaska, J.** 2002. Neuroprotective mechanisms of adenosine action on CNS neurons. *Polish journal of neurology and neurosurgery*, 36:329-336.
- Zeraati, M., Mirnajafi-Zadeh, J., Fathollahi, Y., Namvar, S., Rezvani, M.E.** 2006. Adenosine A₁ and A_{2A} receptors of hippocampal CA1 region have opposite effects on piriform cortex kindled seizures in rats. *Seizure*, 15:41-44.
- Zhang, X., Chen, J., Graham, S.H., Du, L., Kochanek, P.M., Draviam, R., Guo, F., Nathaniel, P.D., Szabo, C., Watkins, S.C., Clark, R.S.** 2002. Intranuclear localization of apoptosis-inducing factor (AIF) and large scale DNA fragmentation after traumatic brain injury in rats and in neuronal cultures exposed to peroxynitrite. *Journal of neurochemistry*, 82:181-191.
- Zhou, M., Panchuk-Voloshina, N.** 1997. A one-step fluorometric method for the continuous measurement of monoamine oxidase activity. *Analytical biochemistry*, 253:169-174.
- Zhu, C., Qiu, L., Wang, X., Hallin, U., Cande, C., Kroemer, G., Hagberg, H., Blomgren, K.** 2003. Involvement of apoptosis-inducing factor in neuronal death after hypoxia–ischemia in the neonatal rat brain. *Journal of neurochemistry*, 86:306-317.
- Zigmond, M.J., Burke, R.E.** 2005. Pathophysiology of Parkinson's disease. (In Davis, K.L., Charney, D., Coyle, J.T., Nemeroff, C. ed. *Neuropsychopharmacology: The Fifth Generation of Progress*, Philadelphia: Lippincott Williams & Wilkins. p.1781-1792.

ADDENDUM


List of ^1NMR and ^{13}NMR spectra.....	133
List of Mass spectrometry data.....	172
List of HPLC data.....	181
Additional NMR spectra (as on cd in hardcopy).....	195

(2E)-3-(3-chlorophenyl)-1-phenylprop-2-en-1-one (**1a**)

¹H-NMR




¹³C-NMR




(E)-3-(3-chlorophenyl)-1-(furan-2-yl)prop-2-en-1-one (**1b**)

¹H-NMR




¹³C-NMR




(2E)-3-(3-chlorophenyl)-1-(5-methylfuran-2-yl)prop-2-en-1-one (**1c**)

¹H-NMR




¹³C-NMR




(2E)-1-(furan-2-yl)-3-(3-methoxyphenyl)prop-2-en-1-one (**1d**)

¹H-NMR




¹³C-NMR




(2E)-3-(3-methoxyphenyl)-1-(5-methylfuran-2-yl)prop-2-en-1-one (**1e**)


¹H-NMR




¹³C-NMR




DEPT 135




DEPT 90




COSY



HSQC




HMBC




(2E)-3-(3,4-dimethoxyphenyl)-1-(5-methylfuran-2-yl)prop-2-en-1-one (1f)

¹H-NMR




¹³C-NMR




(2E)-3-(4-chlorophenyl)-1-(5-methylfuran-2-yl)prop-2-en-1-one (**1g**)

¹H-NMR




¹³C-NMR




(2E)-1-(4-fluorophenyl)-3-(furan-2-yl)prop-2-en-1-one (**1h**)

¹H-NMR




¹³C-NMR




(1*E*)-1-(5-methylfuran-2-yl)-3-[3-oxoprop-1-en-1-yl]benzoic acid (**1i**)

¹H-NMR




¹³C-NMR




(2E)-1-(5-methylfuran-2-yl)-3-[3-(morpholine-4-carbonyl)phenyl]prop-2-en-1-one (**1j**)

¹H-NMR




¹³C-NMR




(2E)-1-(5-methylfuran-2-yl)-3-[3-(4-methylpiperazine-1-carbonyl)phenyl]prop-2-en-1-one (**1k**)

¹H-NMR




¹³C-NMR




(2E)-3-[3-(4-ethylpiperazine-1-carbonyl)phenyl]-1-(5-methylfuran-2-yl)prop-2-en-1-one (**11**)

¹H-NMR




¹³C-NMR




(2E)-1-(5-methylfuran-2-yl)-3-[3-(piperidine-1-carbonyl)phenyl]prop-2-en-1-one (**1m**)

¹H-NMR




¹³C-NMR




(2E)-1-(5-methylfuran-2-yl)-3-[3-(pyrrolidine-1-carbonyl)phenyl]prop-2-en-1-one (**1n**)


¹H-NMR




¹³C-NMR




DEPT 135




DEPT 90




COSY



HSQC




HMBC




4-(3-chlorophenyl)-6-phenylpyrimidin-2-amine (2a)

¹H-NMR




¹³C-NMR




4-(3-chlorophenyl)-6-(furan-2-yl)pyrimidin-2-amine (**2b**)

¹H-NMR




¹³C-NMR




4-(3-chlorophenyl)-6-(5-methylfuran-2-yl)pyrimidin-2-amine (**2c**)

¹H-NMR




¹³C-NMR




4-(furan-2-yl)-6-(3-methoxyphenyl)pyrimidin-2-amine (2d)

¹H-NMR




¹³C-NMR




4-(3-methoxyphenyl)-6-(5-methylfuran-2-yl)pyrimidin-2-amine (2e)

¹H-NMR




¹³C-NMR




4-(3,4-dimethoxyphenyl)-6-(5-methylfuran-2-yl)pyrimidin-2-amine (**2f**)


¹H-NMR




¹³C-NMR




DEPT 135




DEPT 90




COSY



HSQC




HMBC




4-(4-chlorophenyl)-6-(5-methylfuran-2-yl)pyrimidin-2-amine (**2g**)

¹H-NMR




¹³C-NMR




4-(4-fluorophenyl)-6-(5-methylfuran-2-yl)pyrimidin-2-Amine (2h)



¹H-NMR



¹³C-NMR




4-(5-methylfuran-2-yl)-6-[3-(morpholine-4-carbonyl)phenyl]pyrimidin-2-amine (2j)




4-(5-methylfuran-2-yl)-6-[3-(4-methylpiperazine-1-carbonyl)phenyl]pyrimidin-2-amine (**2k**)

¹H-NMR




¹³C-NMR




4-(5-methylfuran-2-yl)-6-[3-(4-ethylpiperazine-1-carbonyl)phenyl]pyrimidin-2-amine (21)

¹H-NMR




¹³C-NMR




4-(5-methylfuran-2-yl)-6-[3-(piperidine-1-carbonyl)phenyl]pyrimidin-2-amine (**2m**)


¹H-NMR




¹³C-NMR




DEPT 135




DEPT 90




COSY



HSQC




HMBC




4-(5-methylfuran-2-yl)-6-[3-(pyrrolidine-1-carbonyl)phenyl]pyrimidin-2-amine (**2n**)

¹H-NMR




¹³C-NMR



Mass spectra


(2E)-3-(3-chlorophenyl)-1-phenylprop-2-en-1-one (1a)

SJ2_HR-c1 #29 RT: 0.77 AV: 1 NL: 1.72E5
T: + c EI Full ms [229.50-257.50]




(2E)-3-(3-chlorophenyl)-1-(furan-2-yl)prop-2-en-1-one (1b)

SJ8_HR-c1 #91 RT: 1.65 AV: 1 NL: 2.70E6
T: + c EI Full ms [217.50-245.50]




(2E)-3-(3-chlorophenyl)-1-(5-methylfuran-2-yl)prop-2-en-1-one (1c)

SJ20_HR-c1 #40 RT: 0.69 AV: 1 NL: 8.70E5
T: + c EI Full ms [241.50-258.50]




(2E)-1-(furan-2-yl)-3-(3-methoxyphenyl)prop-2-en-1-one (**1d**)

SJ10 HR-c1 #20 RT: 0.55 AV: 1 NL: 2.94E6
T: + c EI Full ms [217.50-245.50]




(2E)-3-(3-methoxyphenyl)-1-(5-methylfuran-2-yl)prop-2-en-1-one (**1e**)

SJ22 HR-c1 #30 RT: 0.83 AV: 1 NL: 4.11E5
T: + c EI Full ms [229.50-258.50]




(2E)-3-(3,4-dimethoxyphenyl)-1-(5-methylfuran-2-yl)prop-2-en-1-one (**1f**)

SJ40 HR-c1 #46 RT: 0.72 AV: 1 NL: 9.51E5
T: + c EI Full ms [267.50-284.50]




(2E)-3-(4-chlorophenyl)-1-(5-methylfuran-2-yl)prop-2-en-1-one (**1g**)

SJ30 HR-c1 #22 RT: 0.60 AV: 1 NL: 2.07E6
T: + c EI Full ms [229.50-258.50]




(2E)-1-(4-fluorophenyl)-3-(furan-2-yl)prop-2-en-1-one (**1h**)

SJ24 HR-c1 #18 RT: 0.37 AV: 1 NL: 2.68E6
T: + c EI Full ms [203.50-221.50]




3-[(1E)-3-(5-methylfuran-2-yl)-3-oxoprop-1-en-1-yl]benzoic acid (**1i**)

SJ32 HR1-c1 #34 RT: 0.95 AV: 1 NL: 1.31E5
T: + c EI Full ms [241.50-272.50]




(2E)-1-(5-methylfuran-2-yl)-3-[3-(morpholine-4-carbonyl)phenyl]prop-2-en-1-one (**1j**)

SJ36 HR1-c1 #84 RT: 1.13 AV: 1 NL: 1.80E6
T: + c EI Full ms [317.50-333.50]




(2E)-1-(5-methylfuran-2-yl)-3-[3-(4-methylpiperazine-1-carbonyl)phenyl]prop-2-en-1-one (**1k**)

SJ46 HR1-c1 #58 RT: 0.75 AV: 1 NL: 1.80E6
T: + c EI Full ms [329.50-345.50]




(2E)-3-[3-(4-ethylpiperazine-1-carbonyl)phenyl]-1-(5-methylfuran-2-yl)prop-2-en-1-one (**1l**)

SJ48 HR1-c1 #49 RT: 0.61 AV: 1 NL: 3.20E5
T: + c EI Full ms [341.50-357.50]




(2E)-1-(5-methylfuran-2-yl)-3-[3-(piperidine-1-carbonyl)phenyl]prop-2-en-1-one (**1m**)

SJ58 HR-c1#132 RT: 1.77 AV: 1 NL: 1.38E6
T: + c EI Full ms [317.50-333.50]




(2E)-1-(5-methylfuran-2-yl)-3-[3-(pyrrolidine-1-carbonyl)phenyl]prop-2-en-1-one (**1n**)



Meas. m/z	#	Formula	Score	m/z	err [mDa]	err [ppm]	mSigma	rdb	e ⁻ Conf	N-Rule
310.1448	1	C ₁₉ H ₂₀ N ₁ O ₃	100.00	310.1438	-1.0	-3.4	4.9	10.5	even	ok
	2	C ₁₅ H ₁₆ N ₁ O	9.62	310.1411	-3.7	-12.0	8.8	11.5	even	ok


4-(3-chlorophenyl)-6-phenylpyrimidin-2-amine (**2a**)

SJ6 HR-c2#34 RT: 0.80 AV: 1 NL: 1.92E6
T: + c EI Full ms [267.50-295.50]




4-(3-chlorophenyl)-6-(furan-2-yl)pyrimidin-2-amine (**2b**)

SJ16 HR-c1 #54 RT: 0.81 AV: 1 NL: 1.90E6
T: + c EI Full ms [267.50-283.50]




4-(3-chlorophenyl)-6-(5-methylfuran-2-yl)pyrimidin-2-amine (**2c**)

SJ44 HR-c1 #71 RT: 1.03 AV: 1 NL: 3.50E5
T: + c EI Full ms [279.50-295.50]




4-(3-methoxyphenyl)-6-(furan-2-yl)pyrimidin-2-amine (**2d**)

SJ18 HR-c1 #47 RT: 0.96 AV: 1 NL: 4.70E6
T: + c EI Full ms [253.50-285.50]




4-(3-methoxyphenyl)-6-(5-methylfuran-2-yl)pyrimidin-2-amine (**2e**)

SJ26 HR-c1 #55 RT: 1.31 AV: 1 NL: 4.70E5
T: + c EI Full ms [267.50-295.50]




4-(3,4-dimethoxyphenyl)-6-(5-methylfuran-2-yl)pyrimidin-2-amine (**2f**)

SJ42 HR-c1 #62 RT: 0.97 AV: 1 NL: 3.09E6
T: + c EI Full ms [303.50-322.50]




4-(4-chlorophenyl)-6-(5-methylfuran-2-yl)pyrimidin-2-amine (**2g**)

SJ34 HR-c1 #53 RT: 0.77 AV: 1 NL: 6.16E5
T: + c EI Full ms [279.50-295.50]




4-(4-fluorophenyl)-6-(5-methylfuran-2-yl)pyrimidin-2-Amine (**2h**)

SJ28 HR-c1 #42 RT: 1.14 AV: 1 NL: 2.51E5
T: + c EI Full ms [241.50-270.50]




4-(5-methylfuran-2-yl)-6-[3-(morpholine-4-carbonyl)phenyl]pyrimidin-2-amine (**2j**)

SJ38 HR-c1 #72 RT: 1.01 AV: 1 NL: 7.98E4
T: + c EI Full ms [353.50-372.50]




4-(5-methylfuran-2-yl)-6-[3-(4-methylpiperazine-1-carbonyl)phenyl]pyrimidin-2-amine (**2k**)

SJ50 HR1-c1 #92 RT: 1.37 AV: 1 NL: 1.33E5
T: + c EI Full ms [364.50-385.50]




4-(5-methylfuran-2-yl)-6-[3-(4-ethylpiperazine-1-carbonyl)phenyl]pyrimidin-2-amine (**2l**)

SJ54 HR-c1 #91 RT: 1.60 AV: 1 NL: 3.59E6
T: + c EI Full ms [379.50-406.50]




4-(5-methylfuran-2-yl)-6-[3-(piperidine-1-carbonyl)phenyl]pyrimidin-2-amine (**2m**)

SJ62 HR-c1 #61 RT: 0.82 AV: 1 NL: 4.26E6
T: + c EI Full ms [353.50-371.50]




4-(5-methylfuran-2-yl)-6-[3-(pyrrolidine-1-carbonyl)phenyl]pyrimidin-2-amine (**2n**)

SJ56 HR-c1 #94 RT: 1.14 AV: 1 NL: 5.93E5
T: + c EI Full ms [341.50-356.50]




HPLC chromatograms


(2E)-3-(3-chlorophenyl)-1-phenylprop-2-en-1-one (**1a**)




(2E)-3-(3-chlorophenyl)-1-(furan-2-yl)prop-2-en-1-one (**1b**)




(2E)-3-(3-chlorophenyl)-1-(5-methylfuran-2-yl)prop-2-en-1-one (**1c**)




(2E)-1-(furan-2-yl)-3-(3-methoxyphenyl)prop-2-en-1-one (**1d**)




(2E)-3-(3-methoxyphenyl)-1-(5-methylfuran-2-yl)prop-2-en-1-one (**1e**)




(2E)-3-(3,4-dimethoxyphenyl)-1-(5-methylfuran-2-yl)prop-2-en-1-one (**1f**)




(2E)-3-(4-chlorophenyl)-1-(5-methylfuran-2-yl)prop-2-en-1-one (**1g**)




(2E)-1-(4-fluorophenyl)-3-(furan-2-yl)prop-2-en-1-one (**1h**)




3-[(1*E*)-3-(5-methylfuran-2-yl)-3-oxoprop-1-en-1-yl]benzoic acid (**1i**)




(2*E*)-1-(5-methylfuran-2-yl)-3-[3-(morpholine-4-carbonyl)phenyl]prop-2-en-1-one (**1j**)




(2E)-1-(5-methylfuran-2-yl)-3-[3-(4-methylpiperazine-1-carbonyl)phenyl]prop-2-en-1-one (**1k**)




(2E)-3-[3-(4-ethylpiperazine-1-carbonyl)phenyl]-1-(5-methylfuran-2-yl)prop-2-en-1-one (**1l**)




(2E)-1-(5-methylfuran-2-yl)-3-[3-(piperidine-1-carbonyl)phenyl]prop-2-en-1-one (**1m**)




(2E)-1-(5-methylfuran-2-yl)-3-[3-(pyrrolidine-1-carbonyl)phenyl]prop-2-en-1-one (**1n**)




4-(3-chlorophenyl)-6-phenylpyrimidin-2-amine (**2a**)




4-(3-chlorophenyl)-6-(furan-2-yl)pyrimidin-2-amine (**2b**)




4-(3-chlorophenyl)-6-(5-methylfuran-2-yl)pyrimidin-2-amine (**2c**)




4-(3-methoxyphenyl)-6-(furan-2-yl)pyrimidin-2-amine (**2d**)




4-(3-methoxyphenyl)-6-(5-methylfuran-2-yl)pyrimidin-2-amine (**2e**)




4-(3,4-dimethoxyphenyl)-6-(5-methylfuran-2-yl)pyrimidin-2-amine (**2f**)




4-(4-chlorophenyl)-6-(5-methylfuran-2-yl)pyrimidin-2-amine (**2g**)




4-(4-fluorophenyl)-6-(5-methylfuran-2-yl)pyrimidin-2-Amine (**2h**)




4-(5-methylfuran-2-yl)-6-[3-(morpholine-4-carbonyl)phenyl]pyrimidin-2-amine (**2j**)




4-(5-methylfuran-2-yl)-6-[3-(4-methylpiperazine-1-carbonyl)phenyl]pyrimidin-2-amine (**2k**)




4-(5-methylfuran-2-yl)-6-[3-(4-ethylpiperazine-1-carbonyl)phenyl]pyrimidin-2-amine (**2l**)



4-(5-methylfuran-2-yl)-6-[3-(piperidine-1-carbonyl)phenyl]pyrimidin-2-amine (**2m**)




4-(5-methylfuran-2-yl)-6-[3-(pyrrolidine-1-carbonyl)phenyl]pyrimidin-2-amine (**2n**)




Additional NMR data (As on CD in hard copy):


Compound **1a**




DEPT135




DEPT90




HSQC




COSY




HMBC




Compound **1b**




DEPT135




DEPT90




COSY




HSQC




HMBC




Compound 1c




DEPT135




DEPT90




COSY




HSQC




HMBC




Compound **1d**




DEPT90




DEPT135




COSY




HSQC




HMBC




Compound **1e**




DEPT135




DEPT90




HSQC




HMBC




Compound **1f**




DEPT90




DEPT135




COSY




HSQC




HMBC




Compound **1g**




DEPT135




DEPT90




COSY




HSQC




HMBC




Compound **1h**




CDEPT 135




DEPT90




COSY




HSQC




HMBC




Compound 1i




DEPT90




DEPT135




COSY




HSQC




HMBC




Compound **1j**




DEPT135




DEPT90




COSY




HSQC




HMBC




Compound **1k**




DEPT135




DEPT90




COSY




HSQC




HMBC




Compound 11




DEPT135




DEPT 90




COSY




HSQC




HMBC




Compound 1m




DEPT135




DEPT90




COSY




HSQC




HMBC




Compound **1n**




DEPT 135




DEPT90




COSY




HSQC




HMBC




Compound **2a**




DEPT135




DEPT 90




HSQC




COSY




HMBC




Compound **2b**




DEPT 90




DEPT 135




COSY




HSQC




HMBC




Compound **2c**




DEPT90




DEPT135




COSY




HSQC




HMBC




Compound **2d**




DEPT90




COSY




HSQC




HMBC




Compound **2e**




DEPT135




DEPT90




HMBC




Compound **2f**




DEPT135




DEPT135




COSY




HSQC




HMBC




Compound **2g**




DEPT135




DEPT90




COSY




HSQC




HMBC




Compound **2h**




DEPT135




DEPT90




COSY




HSQC




HMBC




Compound **2j**




DEPT135




DEPT90




COSY




HSQC




HMBC




Compound **2k**




DEPT135




DEPT90




COSY




HSQC




HMBC




Compound **2I**




DEPT135




DEPT 90




COSY




HSQC




HMBC




Compound 2m




DEPT135




DEPT90




COSY




HSQC




HMBC




Compound 2n




DEPT135




DEPT90



COSY



HSQC



HMBC

